

**Saving
children's
lives**

**GAVI Alliance
Pledging
conference for
immunisation**

**L O N D O N
13 JUNE 2011**

Overview of the GAVI Alliance pledging conference for immunisation



Message from the Chair of the GAVI Alliance Board and the Interim CEO of the GAVI Alliance

We look forward to welcoming you to "Saving children's lives - the GAVI Alliance pledging conference for immunisation" in London on 13 June. This meeting is the culmination of a process of making the case for increased investment in life-saving vaccines.

The process began with our meeting in New York last October, where we were hosted by the US and Norway and also supported by the UN Secretary-General who encouraged attendees to increase their funding for GAVI and immunisation in the poorest countries.

Since then, GAVI's friends and supporters – including Presidents, Prime Ministers and Bill and Melinda Gates - have been advocating for this great cause. This has been an achievement of the Alliance as a whole, supported by Richard Manning (former Chair of the OECD's Development Assistance Committee and Director General for Policy at DFID) and Bob McMullan (a former minister in the Australian Government) who, with the staff of the secretariat, have facilitated the process, and the Government of the United Kingdom which will host this meeting and which has used every opportunity to make the case for GAVI. To all, we extend our heartfelt thanks and appreciation.

We now need to turn this powerful advocacy into investment.

13 June will be about donors making firm commitments to future funding, but it will also be the opportunity for other members of the Alliance to make pledges that are essential for achieving GAVI's mission to save children's lives and protect people's health. We are looking forward to commitments from GAVI eligible countries, the Alliance's multilateral partners, and vaccine producers.

We look forward to seeing you in London at "Saving children's lives – the GAVI Alliance pledging conference for immunisation", where we can together make a significant contribution towards achieving the health Millennium Development Goals.

Yours sincerely,

A handwritten signature in black ink, reading "Dagfinn Høybråten".

Dagfinn Høybråten
Chair, the GAVI Alliance Board

A handwritten signature in blue ink, reading "Helen Evans".

Helen Evans
Interim CEO, the GAVI Alliance

The GAVI Alliance pledging conference for immunisation

Every 20 seconds, a child dies of a vaccine-preventable disease.

On June 13, 2011 global leaders will gather in London to drive a new, forceful impetus to immunisation efforts in the world's poorest countries. The power of vaccines together with bold leadership can deliver real progress on the Millennium Development Goals.

Hosted by senior leaders of the United Kingdom and with the participation of heads of state and ministers, "Saving children's lives - the GAVI Alliance pledging conference for immunisation" will bring together government donors and private foundation leaders, ministers from countries rolling out new vaccines, as well as vaccine manufacturers, the private sector and advocates. Their collective aim will be to raise the resources needed to accelerate a reduction in worldwide child mortality associated with vaccine-preventable diseases. US\$ 3.7 billion in additional new donor contributions to the GAVI Alliance for 2011-2015 will immunise nearly 250 million children and save four million lives.

Addressing global health priorities and saving four million lives

A successful pledging conference will contribute to the United Nations Secretary-General's Global Strategy for Women's and Children's Health, help to fulfil the objectives of the G8's Muskoka Initiative for Maternal and Child Health, and to accelerate progress towards the Millennium Development Goals (MDGs).

Vaccines offer a historic opportunity to reduce child mortality, the target of MDG 4. By expanding routine immunisation coverage of pentavalent vaccines, the 5-in-1 shot against diphtheria, tetanus, pertussis, hepatitis B and Hib (*Haemophilus influenzae* type b), and by introducing new pneumococcal and rotavirus vaccines against the leading child killers, pneumonia and diarrhoea, GAVI can help countries tackle the high numbers of child deaths.

The economic and social benefits of healthy, immunised children accrue across all the MDGs. As well as being spared the tragic death of a child, families avoid the crippling costs of hospitalisation, allowing them to break out of a cycle of poverty and ill health. Protecting children from illness and disability enables them to attend school, and improves their ability to learn. Parents are freed from the responsibility of caring for sick or disabled children, enabling other productive activities. Parents confident that their children will survive are more likely to limit family size, which in turn exposes the mother to less risk of maternal death.

Increasing resources for immunisation

The pledging conference seeks to fully fund country demand for vaccines through a three-fold approach: 1) increased levels of donor contributions and innovative finance commitments; 2) reductions in vaccine prices; and 3) commitment to co-financing from recipient countries, with the aim of sustainability after graduation from GAVI support for those countries able to do so.

Donor contributions and innovative financing commitments: It is anticipated that at the pledging conference donors will make significant long-term pledges, more than doubling their current level of direct contributions. Donors are also encouraged to donate to innovative funding mechanisms, including the International Finance Facility for Immunisation (IFFIm).

To date, IFFIm has raised a cumulative US\$ 3.2 billion in additional funds by issuing bonds in capital markets, thereby converting long-term government pledges into immediately available resources. IFFIm increases financial efficiency and funding predictability through its ability to draw quickly from the market to address liquidity constraints and thereby avoid disruptions to immunisation programmes. It is also a powerful tool for new donors to make a significant contribution to GAVI starting from a relatively modest cash commitment.

Reduced vaccine prices: GAVI fosters a healthy, competitive vaccine market by pooling demand from developing countries, attracting new manufacturers from emerging economies, and increasing competition to drive down prices. For example, hepatitis B vaccine prices have dropped by 64% since 2000. However, prices for all vaccines have not fallen as rapidly as envisioned. Having elevated market shaping to a strategic goal, GAVI is actively pursuing a more aggressive approach to reducing vaccine prices and to redesigning its supply and procurement strategy.

Co-financing: In 2010, over 50 implementing countries co-financed vaccines, of which 19 countries paid more than their required minimum co-payment, totalling more than US\$ 28 million. GAVI's new co-financing policy strengthens national ownership and the capacity of GAVI-supported countries to sustain expanded immunisation programmes.

What fully funding GAVI to 2015 will buy

- **Nearly 250 million children immunised, four million future deaths averted;** almost doubling GAVI's results over the first decade.
- New offensive against the two biggest killers of children, pneumonia and diarrhoea, through **accelerating the introduction of pneumococcal and rotavirus vaccines.**
- Control of deadly meningitis epidemics through the introduction of a **new vaccine against meningitis A** in countries of the African Meningitis Belt.
- Introduction of **HPV vaccines** that protect women against cervical cancer; and the other prioritised vaccines, **Japanese encephalitis, rubella and typhoid.**
- **Strengthened routine immunisation programmes** as part of integrated health services for women and children.

GAVI's proven track record of cost-effectiveness, efficiency and innovation

- **Documented results:** 288 million children immunised and over five million deaths averted in the last decade in 72 of the world's poorest countries. Increased immunisation coverage of diphtheria-tetanus-pertussis vaccine (DTP3) to a record high of 79%. Spurred the rapid introduction of the first anti-cancer vaccine in poor countries, hepatitis B, preventing liver cancer.
- **Efficiency and impact:** United Kingdom Multilateral Aid Review 2011 places GAVI at the top of multilateral development organisations for value for money, organisational strengths and contribution to development.
- **Value for money:** Expanded immunisation coverage for children ranked among the top five most cost-effective solutions to major global challenges by an international think tank (Copenhagen Consensus, 2008).

- **Aid effectiveness and harmonisation:** Use of country-based systems and partners that deliver programmes in line with principles of aid effectiveness; flexible health systems strengthening support in line with national plans and strategies; develop the Health Systems Funding Platform for harmonised health systems support.
- **Innovative finance:** Pioneered new ways of financing development. IFFIm leverages long-term donor commitments to issue bonds on the capital markets, raising additional resources and contributing to the certainty of funding that underpins long-term vaccine programmes. The Advance Market Commitment (AMC) has accelerated the launch of pneumococcal vaccines in developing countries within months of their introduction in industrialised countries, and at lower prices - US\$ 3.50 per dose, less than 5% of the public market price in the USA.
- **Engaging vaccine markets:** The GAVI business model fosters a healthy, competitive vaccine market by pooling demand from developing countries and providing predictable financing to meet demand, attracting new manufacturers from emerging economies and increasing competition to drive down prices.
- **Successful public private partnership:** The success of the GAVI business model is driven by an inclusive partnership with developing countries, donor governments, WHO, UNICEF, the World Bank, the vaccine industry in industrialised and developing countries, research and technical agencies, civil society organisations, the Bill & Melinda Gates Foundation and other private philanthropists.

List of meeting documents

- 1 Overview of the GAVI Alliance pledging conference for immunisation**
- 2 Investing in vaccines**
- 3 Resource needs 2011-2015**
- 4 GAVI Strategy & Business Plan**
- 5 Donor commitments and contributions**
- 6a Market shaping: access to low and sustainable vaccine prices**
- 6b Market shaping: strategic considerations for a healthy vaccine marketplace**
- 7 Building ownership and sustainability: country co-financing of vaccines**
- 8 Health system strengthening**
- 9 Innovative finance**
- 10 Protecting women's and children's health**

All documents are also available online at:

www.gavialliance.org/2011_pledging_conference_documents

List of GAVI Alliance policies

GAVI policies are available on the GAVI Alliance website. The following may be of particular interest to participants:

- Country Eligibility Policy
- Graduation Policy
- Revised Vaccine Co-financing Policy
- Pilot Prioritisation Mechanism
- Gender Policy
- Transparency and Accountability Policy

These documents are available at:

http://www.gavialliance.org/2011_pledging_conference_policies



2 Chemin des Mines
1202 Geneva
Switzerland

Tel. +41 22 909 65 00
Fax +41 22 909 65 55

www.gavialliance.org
info@gavialliance.org